Document Detail


New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence.
MedLine Citation:
PMID:  22946769     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is a potent risk factor for stroke and transient ischemic attack. Most patients with AF receive antithrombotic stroke prophylaxis, often in the form of a vitamin K antagonist, typically warfarin. Drug treatment with warfarin is associated with significant management issues, such as an unpredictable dose response necessitating dose adjustments, frequent laboratory monitoring, and multiple interactions with other medications, as well as foods. A new generation of novel anticoagulants has emerged that includes dabigatran etexilate, a direct thrombin inhibitor, and rivaroxaban and apixaban, both highly selective factor Xa inhibitors. These newer agents possess a highly predictable pharmacokinetic-pharmacodynamic relationship, allowing for fixed dosing and no necessity for routine laboratory monitoring; additionally these agents have minimal drug interactions. Dabigatran etexilate and apixaban are both twice-daily medications, whereas rivaroxaban is administered once daily for stroke prophylaxis. The impact of dosing frequency on medication adherence with these agents has not been prospectively evaluated; however, the frequency of dosing intervals has been shown to affect medication adherence, which in turn may influence patient outcomes.
Authors:
Stephen Kopecky
Related Documents :
21526689 - Emergency medical readmission: long-term trends and impact on mortality.
17575959 - Endocrinology and expectations in 1930s america: louis berman's ideas on new creations ...
19297629 - Let's think about human factors, not human failings.
18428219 - References to molecular biology techniques.
22277399 - Diagnosis and therapies of refractory migraine.
18165959 - Cytotoxicity of nanoparticles.
21526689 - Emergency medical readmission: long-term trends and impact on mortality.
19336059 - Investigation of accolate and singulair for treatment of capsular contracture yields sa...
10764549 - Gonadotropin-releasing hormones in the brain and pituitary of the teleost, the white su...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of cardiovascular drugs : drugs, devices, and other interventions     Volume:  12     ISSN:  1179-187X     ISO Abbreviation:  Am J Cardiovasc Drugs     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100967755     Medline TA:  Am J Cardiovasc Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  287-94     Citation Subset:  IM    
Affiliation:
Mayo Clinic, Rochester, MN, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Real-Time Telehealth for COPD Self-Management Using Skype™
Next Document:  Asymmetric Synthesis of gem-Difluoromethylenated Dihydroxypyrrolizidines and Indolizidines.